Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.

Julie KolwelterAgnes BoschSusanne JungLena StabelDennis KannenkerilChristian OttPeter BramlageMario SchifferStephan AchenbachRoland E Schmieder

Published in: ESC heart failure (2021)

We found an improvement of vascular function after treatment with empagliflozin that indicates decreased afterload of the left ventricle and may contribute to the beneficial effects of SGLT2 inhibition in HF.

Keyphrases

pulmonary hypertension
pulmonary artery
ejection fraction
left ventricular
coronary artery
congenital heart disease